TY - JOUR
T1 - Topical therapeutic efficacy of 9-(2-hydroxyethoxymethyl)guanine and 5-iodo-5'-amino-2',5'-dideoxyuridine on oral infection with herpes simplex virus in mice
AU - Park, N. H.
AU - Pavan-Langston, D.
AU - Hettinger, M. E.
AU - McLean, S. L.
AU - Albert, D. M.
AU - Lin, T. S.
AU - Prusoff, W. H.
N1 - Funding Information:
This study was supported in part by research grants no. ENYS-02268 and EY-00208 to Dr. Park from the National Eye Institute, National Institutes of Health; the Prince Charitable Trusts; the Eye Research Fund of the Massachusetts Lions; and research grant no. CA-05262 from the National Cancer Institute. Dr. Lin is supported in part by a grant from the Bristol Meyers Company.
PY - 1980
Y1 - 1980
N2 - The therapeutic efficacy of two new antiviral agents, 5-iodo-5'-amino-2', 5'-dideoxyuridine (AIdUrd) and 9-(2-hydroxyethoxymethyl)guanine (ACV), in the model of mouse lip inoculated with herpes simplex virus type 2 is reported. The effects on development of clinical lesions, viral replication in the inoculated lips, and establishment of latent viral infection in the trigeminal ganglia were observed. The earlier the treatment with AIdUrd and ACV was initiated after inoculation, the better was the chemotherapeutic effect. AIdUrd and ACV treatment, when initiated 48 and 72 hr after inoculation, respectively, showed no chemotherapeutic efficacy. Establishment of viral latent infection sensory ganglia was significantly prevented only when ACV treatment was initiated very early (1 or 3 hr) after inoculation. The results indicate that both drugs have significant antiviral activity, in part dependent on the time of initiation of therapy, and that ACV is superior to AIdUrd as a topical agent for therapy of herpes simplex virus type 2 infections.
AB - The therapeutic efficacy of two new antiviral agents, 5-iodo-5'-amino-2', 5'-dideoxyuridine (AIdUrd) and 9-(2-hydroxyethoxymethyl)guanine (ACV), in the model of mouse lip inoculated with herpes simplex virus type 2 is reported. The effects on development of clinical lesions, viral replication in the inoculated lips, and establishment of latent viral infection in the trigeminal ganglia were observed. The earlier the treatment with AIdUrd and ACV was initiated after inoculation, the better was the chemotherapeutic effect. AIdUrd and ACV treatment, when initiated 48 and 72 hr after inoculation, respectively, showed no chemotherapeutic efficacy. Establishment of viral latent infection sensory ganglia was significantly prevented only when ACV treatment was initiated very early (1 or 3 hr) after inoculation. The results indicate that both drugs have significant antiviral activity, in part dependent on the time of initiation of therapy, and that ACV is superior to AIdUrd as a topical agent for therapy of herpes simplex virus type 2 infections.
UR - http://www.scopus.com/inward/record.url?scp=0018900358&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0018900358&partnerID=8YFLogxK
U2 - 10.1093/infdis/141.5.575
DO - 10.1093/infdis/141.5.575
M3 - Article
C2 - 6966305
AN - SCOPUS:0018900358
SN - 0022-1899
VL - 141
SP - 575
EP - 579
JO - Journal of Infectious Diseases
JF - Journal of Infectious Diseases
IS - 5
ER -